(Reuters) – The U.S. Food and Drug Administration has approved Incyte’s eczema treatment for children aged between 2 and 11 years, the company said on Thursday.
It was previously approved for individuals aged 12 years and older.
The Wilmington, Delaware-based company has been banking on the treatment, called Opzelura, as a key growth driver after the anticipated loss of exclusivity of its blockbuster blood disorder drug, Jakafi.
The approval was based on results from a late-stage trial, which demonstrated the treatment achieved higher efficacy when compared with a non-medicated cream.
Eczema, or atopic dermatitis, is a skin condition marked by dry, itchy and inflamed patches.
(Reporting by Unnamalai L and Puyaan Singh in Bengaluru; Editing by Krishna Chandra Eluri)
Brought to you by www.srnnews.com
